Navigate regulatory complexity, prescriber concentration risk, and sterile compounding liability before you close on a compounding pharmacy acquisition.
Find Compounding Pharmacy Acquisition TargetsAcquiring a compounding pharmacy offers durable cash flow and high barriers to entry, but demands rigorous due diligence. Regulatory exposure under USP 795/797/800, prescriber dependency, and pharmacist-in-charge succession are deal-defining risks that require structured review before committing capital.
Validate the pharmacy's compliance posture with state boards, FDA, and USP standards before proceeding further. Regulatory findings discovered late can collapse a deal or trigger post-closing liability.
Pull the full license history for disciplinary actions, consent orders, or pending investigations. Any unresolved citations must be resolved prior to closing.
Request all FDA correspondence including inspection reports and 483 observations. Prior warning letters signal systemic quality failures that may resurface under new ownership.
Review cleanroom ISO certifications, HVAC validation records, beyond-use dating policies, and hazardous drug handling SOPs to confirm current compliance status.
Assess the sustainability and transferability of revenue streams, including payer mix, prescription volume trends, and SDE adjustments before accepting the seller's valuation narrative.
Identify the top 10 prescribers by revenue contribution. Any single prescriber exceeding 15% of sales represents a material concentration risk requiring earnout protection.
Segment revenue by compounding category. Sterile formulations carry higher margins but greater liability; confirm the revenue mix aligns with facility certifications and staffing capabilities.
Analyze cash-pay versus insurance reimbursement ratios and identify any pending PBM or insurance audits that could trigger retroactive clawbacks post-closing.
Evaluate the pharmacy's operational infrastructure, staffing depth, and ownership transition plan to ensure the business can sustain performance under new management.
Confirm the buyer holds or can obtain PIC licensure in the state. Identify a cross-trained backup pharmacist who can serve as interim PIC during transition.
Review written SOPs for all compounding processes, quality control testing, and complaint handling. Undocumented processes indicate key-person dependency and regulatory vulnerability.
Assess cleanroom age, equipment calibration records, and HVAC systems. Identify near-term capital needs for USP 800 upgrades that would reduce post-closing free cash flow.
Verify the Compounding Pharmacy acquisition qualifies for SBA financing, the purchase price is supportable by the verified cash flow, and the deal structure protects the buyer's downside.
Confirm the Compounding Pharmacy meets SBA 7(a) eligibility requirements: the business is for-profit, U.S.-based, within SBA size standards, and the buyer meets personal financial requirements. Some industries have specific SBA restrictions — verify before LOI.
Model verified normalized EBITDA against projected SBA loan payments at current rates. A $1M SBA 7(a) loan at 10.5% over 10 years costs approximately $13,000/month. The Compounding Pharmacy must generate at least 1.25x debt service coverage after a market-rate manager salary to pass underwriting.
Confirm the seller note is properly subordinated to the SBA loan and goes on 24-month standby as required by SBA rules. If an earnout is included, define exact measurement metrics, time period, and dispute resolution process before signing the purchase agreement.
Before signing a Letter of Intent, request these documents from the seller. Missing or incomplete items are a red flag — not a reason to proceed without them.
Most states require the buyer or a designated employee to hold a pharmacist-in-charge license. Non-pharmacist investors typically partner with or hire a licensed PIC before or immediately at closing.
High prescriber concentration typically triggers earnout provisions tied to retention of key referring physicians, often 12–24 months post-close, protecting the buyer against immediate revenue cliff risk.
PCAB-accredited pharmacies with clean regulatory histories and diversified prescriber bases typically trade at 3.5–6x SDE. Regulatory risk, payer mix, and sterile compounding capabilities significantly influence where a deal lands in that range.
Yes. Compounding pharmacies are SBA 7(a) eligible. Most deals combine SBA financing with a seller note of 10–15%, and lenders will scrutinize regulatory history and prescriber concentration during underwriting.
More Compounding Pharmacy Guides
DealFlow OS surfaces targets with seller signals and motivation scores — so you know before you start diligence. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers